Type 2 diabetes and heart failure - how to optimize cooperation of cardiologist and diabetologist

被引：2

作者：

Kubickova, Marketa ^{[1
]}

Bis, Josef ^{[2
]}

机构：

[1] Fak Nemocnice Hradec Kralove, Diabetol Ctr, Interni Gerontometab Klin 3, Sokolska 581, Hradec Kralove 50005, Czech Republic

[2] Fak Nemocnice Hradec Kralove, Kardioctr, Interni Kardioangiol Klin 1, Hradec Kralove, Czech Republic

来源：

COR ET VASA | 2021年 / 63卷 / 03期

关键词：

Cardioprotective effects; Chronic heart failure; Dapagliflozin; Nephroprotective effects; SGLT2; inhibition; Type; 2; diabetes; CARDIOVASCULAR OUTCOMES; MORTALITY;

D O I：

10.33678/cor.2021.084

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Heart failure and type 2 diabetes mellitus often occur together and are associated with poor prognosis and high mortality. Cardiovascular studies with SGLT2 inhibition carried out in recent years in type 2 diabetics have shown its beneficial effect on the reduction of hospitalization for heart failure. This beneficial effect demonstrated with all gliflozins (empagliflozin, dapagliflozin, canagliflozin) became the subject of further research and thus hope for the treatment of heart failure. DAPA-HF studies with dapagliflozin aimed at patients with chronic heart failure and reduced EF (HFrEF) confirmed a decrease in hospitalization for heart failure and a decrease in cardiovascular and overall mortality in patients treated with dapagliflozin regardless of the presence of diabetes. Dapagliflozin is therefore not only an antidiabetic, but becomes also a useful drug for the treatment of the chronic heart failure with reduced EF.

引用

页码：373 / 377

页数：5

共 19 条

[1] Aiglova R, 2020, BIOMED PAP, V164
[2] 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2021
不详
[J]. DIABETES CARE, 2021, 44 : S111 - S124
[3] Heart failure prevalence, incidence, and mortality in the elderly with diabetes
Bertoni, AG
Hundley, WG
Massing, MW
Bonds, DE
Burke, GL
Goff, DC
[J]. DIABETES CARE, 2004, 27 (03) : 699 - 703
[4] Trends and Disparities in Cardiovascular Mortality Among US Adults With and Without Self-Reported Diabetes, 1988-2015
Cheng, Yiling J.
Imperatore, Giuseppina
Geiss, Linda S.
Saydah, Sharon H.
Albright, Ann L.
Ali, Mohammed K.
Gregg, Edward W.
[J]. DIABETES CARE, 2018, 41 (11) : 2306 - 2315
[5] Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016
Vos, Theo
Abajobir, Amanuel Alemu
Abbafati, Cristiana
Abbas, Kaja M.
Abate, Kalkidan Hassen
Abd-Allah, Foad
Abdulle, Abdishakur M.
Abebo, Teshome Abuka
Abera, Semaw Ferede
Aboyans, Victor
Abu-Raddad, Laith J.
Ackerman, Ilana N.
Adamu, Abdu Abdullahi
Adetokunboh, Olatunji
Afarideh, Mohsen
Afshin, Ashkan
Agarwal, Sanjay Kumar
Aggarwal, Rakesh
Agrawal, Anurag
Agrawal, Sutapa
Kiadaliri, Aliasghar Ahmad
Ahmadieh, Hamid
Ahmed, Muktar Beshir
Aichour, Amani Nidhal
Aichour, Ibtihel
Aichour, Miloud Taki Eddine
Aiyar, Sneha
Akinyemi, Rufus Olusola
Akseer, Nadia
Al Lami, Faris Hasan
Alahdab, Fares
Al-Aly, Ziyad
Alam, Khurshid
Alam, Noore
Alam, Tahiya
Alasfoor, Deena
Alene, Kefyalew Addis
Ali, Raghib
Alizadeh-Navaei, Reza
Alkerwi, Ala'a
Alla, Francois
Allebeck, Peter
Allen, Christine
Al-Maskari, Fatma
Al-Raddadi, Rajaa
Alsharif, Ubai
Alsowaidi, Shirina
Altirkawi, Khalid A.
Amare, Azmeraw T.
Amini, Erfan
[J]. LANCET, 2017, 390 (10100) : 1211 - 1259
[6] Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial
Gerstein, Hertzel C.
Colhoun, Helen M.
Dagenais, Gilles R.
Diaz, Rafael
Lakshmanan, Mark
Pais, Prem
Probstfield, Jeffrey
Riesmeyer, Jeffrey S.
Riddle, Matthew C.
Ryden, Lars
Xavier, Denis
Atisso, Charles Messan
Dyal, Leanne
Hall, Stephanie
Rao-Melacini, Purnima
Wong, Gloria
Avezum, Alvaro
Basile, Jan
Chung, Namsik
Conget, Ignacio
Cushman, William C.
Franek, Edward
Hancu, Nicolae
Hanefeld, Markolf
Holt, Shaun
Jansky, Petr
Keltai, Matyas
Lanas, Fernando
Leiter, Lawrence A.
Lopez-Jaramillo, Patricio
Cardona Munoz, Ernesto German
Pirags, Valdis
Pogosova, Nana
Raubenheimer, Peter J.
Shaw, Jonathan E.
Sheu, Wayne H-H
Temelkova-Kurktschiev, Theodora
[J]. LANCET, 2019, 394 (10193) : 121 - 130
[7] Dapagliflozin in Patients with Chronic Kidney Disease
Heerspink, Hiddo J. L.
Stefansson, Bergur V.
Correa-Rotter, Ricardo
Chertow, Glenn M.
Greene, Tom
Hou, Fan-Fan
Mann, Johannes F. E.
McMurray, John J. V.
Lindberg, Magnus
Rossing, Peter
Sjostrom, C. David
Toto, Roberto D.
Langkilde, Anna-Maria
Wheeler, David C.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (15) : 1436 - 1446
[8] Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
Hernandez, Adrian F.
Green, Jennifer B.
Janmohamed, Salim
D'Agostino, Ralph B., Sr.
Granger, Christopher B.
Jones, Nigel P.
Leiter, Lawrence A.
Rosenberg, Anne E.
Sigmon, Kristina N.
Somerville, Matthew C.
Thorpe, Karl M.
McMurray, John J. V.
Del Prato, Stefano
[J]. LANCET, 2018, 392 (10157) : 1519 - 1529
[9] Prognostic Implications of Type 2 Diabetes Mellitus in Ischemic and Nonischemic Heart Failure
Johansson, Isabelle
Dahlstrom, Ulf
Edner, Magnus
Nasman, Per
Ryden, Lars
Norhammar, Anna
[J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 68 (13) : 1404 - 1416
[10] Atherosclerosis and Microvascular Complications: Results From the Canadian Study of Longevity in Type 1 Diabetes
Lovshin, Julie A.
Bjornstad, Petter
Lovblom, Leif E.
Bai, Johnny-Wei
Lytvyn, Yuliya
Boulet, Genevieve
Farooqi, Mohammed A.
Santiago, Sam
Orszag, Andrej
Scarr, Daniel
Weisman, Alanna
Keenan, Hillary A.
Brent, Michael H.
Paul, Narinder
Bril, Vera
Perkins, Bruce A.
Cherney, David Z. I.
[J]. DIABETES CARE, 2018, 41 (12) : 2570 - 2578

← 1 2 →